Data Standards: Technical ‘Postmortem’ Could Clarify US FDA Preferences, Industry Says

Feedback on application-specific data submission issues that vexed the agency but were not onerous enough to warrant a refuse-to-file letter would help inform future filings and reduce variation across sponsors, industry representatives say at meeting on analytical data standards.